These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16391296)

  • 1. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry.
    Wachtel M; Runge T; Leuschner I; Stegmaier S; Koscielniak E; Treuner J; Odermatt B; Behnke S; Niggli FK; Schäfer BW
    J Clin Oncol; 2006 Feb; 24(5):816-22. PubMed ID: 16391296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics.
    Grass B; Wachtel M; Behnke S; Leuschner I; Niggli FK; Schäfer BW
    Histopathology; 2009 Jun; 54(7):873-9. PubMed ID: 19469909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
    van Gaal JC; Flucke UE; Roeffen MH; de Bont ES; Sleijfer S; Mavinkurve-Groothuis AM; Suurmeijer AJ; van der Graaf WT; Versleijen-Jonkers YM
    J Clin Oncol; 2012 Jan; 30(3):308-15. PubMed ID: 22184391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
    Smith LM; Anderson JR; Coffin CM
    Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior.
    Staibano S; Franco R; Tranfa F; Mezza E; Lo Muzio L; Strianese D; Errico ME; Bufo P; Ferrara G; Somma P; Mansueto G; Greco I; Fiorillo A; Bonavolontà G; De Rosa G
    Anticancer Res; 2004; 24(1):249-57. PubMed ID: 15015604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis.
    Coffin CM; Rulon J; Smith L; Bruggers C; White FV
    Mod Pathol; 1997 Dec; 10(12):1175-87. PubMed ID: 9436961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
    Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
    Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
    Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues.
    Kumar S; Perlman E; Harris CA; Raffeld M; Tsokos M
    Mod Pathol; 2000 Sep; 13(9):988-93. PubMed ID: 11007039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of nuclear morphometry in prediction of prognosis for rhabdomyosarcoma in children.
    Kazanowska B; Jelen M; Reich A; Tarnawski W; Chybicka A
    Histopathology; 2004 Oct; 45(4):352-9. PubMed ID: 15469473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kit expression in spindle cell rhabdomyosarcoma can possibly create a different approach for its tumorigenesis and therapy.
    Diniz G; Aktas S; Ortac R; Tunakan M; Unlu I; Vergin C
    Pathol Res Pract; 2006; 202(9):671-7. PubMed ID: 16860492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
    Paner GP; McKenney JK; Epstein JI; Amin MB
    Am J Surg Pathol; 2008 Jul; 32(7):1022-8. PubMed ID: 18469707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of a muscle ankyrin-repeat protein, Arpp, in paraffin-embedded tumors: evaluation of Arpp as a tumor marker for rhabdomyosarcoma.
    Ishiguro N; Motoi T; Osaki M; Araki N; Minamizaki T; Moriyama M; Ito H; Yoshida H
    Hum Pathol; 2005 Jun; 36(6):620-5. PubMed ID: 16021567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis.
    Stock N; Chibon F; Binh MB; Terrier P; Michels JJ; Valo I; Robin YM; Guillou L; Ranchère-Vince D; Decouvelaere AV; Collin F; Birtwisle-Peyrottes I; Gregoire F; Aurias A; Coindre JM
    Am J Surg Pathol; 2009 Dec; 33(12):1850-9. PubMed ID: 19898221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study.
    Gordon T; McManus A; Anderson J; Min T; Swansbury J; Pritchard-Jones K; Shipley J; ;
    Med Pediatr Oncol; 2001 Feb; 36(2):259-67. PubMed ID: 11452933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.
    Davicioni E; Anderson MJ; Finckenstein FG; Lynch JC; Qualman SJ; Shimada H; Schofield DE; Buckley JD; Meyer WH; Sorensen PH; Triche TJ
    Am J Pathol; 2009 Feb; 174(2):550-64. PubMed ID: 19147825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
    Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
    Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.